Accuracy of Predicting Residual Disease and Disease Progression During Active Surveillance for Esophageal Cancer.

ABSTRACT:

Background

To date, active surveillance has been non-inferior to standard surgery for patients with esophageal cancer, achieving a clinical complete response (CCR) after neoadjuvant chemoradiotherapy (nCRT). However, two thirds of patients have residual disease detected 12 weeks after nCRT and undergo surgery. At 12 weeks, nearly half of the patients with CCR will experience locoregional regrowth. This study aimed to identify routine predictive factors for achieving (sustained) CCR to improve patient selection for active surveillance.

Methods

Data from the SANO trial were analyzed, including data of patients who underwent nCRT for esophageal cancer. Logistic regression assessed predictors of CCR at 12 weeks, with potential factors including age, sex, WHO performance status,

SUBMITTER: Gangaram Panday SSG 

PROVIDER: S-EPMC12765740 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature